Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B

PharmacoEconomics

Volumn 17, Issue 5, 2000, Pages 409-427

  Crowley, Steven J ^a,d   Tognarini, David ^a   Desmond, Paul V ^b   Lees, Michael ^c  

^a GLAXOSMITHKLINE   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

^c Medical Technology Assessment Group   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG COST; DRUG INDICATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SEROCONVERSION; STATISTICAL MODEL;

EID: 0034049810     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017050-00001     Document Type: Article

References (70)

1. 1. World Health Organization. Hepatitis B fact sheet WHO/204 [internet web page]. Available from: URL: http://www.who.int/inf-fs/en/fact204.html [Accessed 2000 Mar 13]
2. 2. Purcell RH. The discovery of the hepatitis viruses. Gastroenterology 1993; 104: 955-63
3. 3. Davey S. State of the world's vaccines and immunisation. Geneva: World Health Organization, 1996
4. 4. Farell GC. Chronic viral hepatitis. Med J Aust 1998; 168: 619-26
5. 5. Mast EE, Alter MJ. Epidemiology of viral hepatitis: an overview. Semin Virol 1993; 4: 273-83
6. 6. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-44
7. 7. Gust ID. Immunisation against hepatitis B in Taiwan. Gut 1996; 38 Suppl. 2; S67-8
8. 8. Nicoll A, Locarnini S. Present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 1997; 12: 843-53
9. 9. Niederau C, Heintges T, Lange S, et al. Long term follow up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7
10. 10. Lau DT, Everhart J, Kleiner DL, et al. Long term follow-up of patients with chronic hepatitis B treated with interferon alpha. Gastroenterology 1997; 113: 1660-7
11. 11. Hope RL, Welman M, Dingley J, et al. Interferon alpha for chronic active hepatitis B, long term follow-up of 62 patients: outcomes and predictors of response. Med J Aust 1995; 162: 8-11
12. 12. Tine F, Liberati A, Craxi A, et al. Interferon treatment in patients with chronic hepatitis B; a meta-analysis of the published literature. J Hepatol 1993; 18: 154-62
13. 13. Lampertico P, Del Ninno E, Maniz A, et al. A randomised, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-5
14. 14. Burt MJ, Ross AG, Schroeder BA, et al. Evaluation of alpha interferon for the treatment of chronic hepatitis B infection in Christchurch. N Z Med J 1996; 109: 162-4
15. 15. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-23
16. 16. Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998; 59: 563-78
17. 17. Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pretreatment variables: results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21: 646-55
18. 18. Krogsgaard D, The Long-term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP) Executive Team on Antiviral Treatment. The long term effect of treatment with interferon alpha 2A in chronic hepatitis B, J Viral Hepat 1998; 5: 389-97
19. 19. Lok AS, Chung HT, Liu VW, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-8
20. 20. Lok AS, Lai CL, Wu PC, et al. Long-term follow-up in a randomised controlled trial of recombinant alpha2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; II: 298-302
21. 21. Guptan RK, Thakur V, Malhortra V, et al. Low-dose recombinant interferon therapy in anti HBe-positive chronic hepatitis B in Asian Indians. J Gastroenterol Hepatol 1998; 13: 675-9
22. 22. Zhang X, Zoulim F, Haberseber I, et al. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of Hbe antigen negative chronic hepatitis B. J Med Virol 1996; 48: 8-16
23. 23. Dejongh FE, Janssen HL, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5
24. 24. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8
25. 25. Dienstag J, Schiff E, Wright T, et al. Lamivudine treatment for one year in previously untreated US hepatitis B patients: histological improvement and hepatitis e-antigen (HBeAg) seroconversion [abstract]. Gastroenterology 1998; 114: A1235
26. 26. Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who had previously failed interferon therapy [abstract]. Hepatology 1998; 28 (4 Pt 2): 388A
27. 27. Heathcote J, Schalm SW, Cianciara J, et al. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection [abstract]. J Hepatol 1998; 28 Suppl. 1: 43
28. 28. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six month randomised dose-ranging study. Gastroenterology 1997; 113: 1258-63
29. 29. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61
30. 30. Goodman Z, Dhillon AP, Wu PC, et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B [abstract]. J Hepatol 1999; 30 Suppl. 1: 59
31. 31. Lueng N, Wu PC, Tsang S, et al. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine [abstract]. Hepatology 1998; 28: 489A
32. 32. Liaw YF, Lai CL, Leung NWY, et al. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multi-centre study in Asia [abstract]. Gastroenterology 1998; 114: 1289A
33. 33. Lueng NWY, Lai CL, Chang TT, et al. Three year lamivudine therapy in chronic HBV [abstract]. J Hepatol 1999; 30 Suppl. 1: 59
34. 34. Van Thiel DH, Friedlander L, Kania R, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997; 44: 808-12
35. 35. Picardi M, Selleri C, De Rosa G, et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogenic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 1267-9
36. 36. Chan TM, Wu PC, Li FK, et al. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115: 177-81
37. 37. Faraidy KA, Yoshida EM, Davis JE, et al. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64: 926-8
38. 38. Kaldor JM, Plant AJ, Thompson SC, et al. The incidence of hepatitis B infection in Australia: an epidemiological review. Med J Aust 1996; 165: 322-6
39. 39. Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2B treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75
40. 40. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg 1998; 61: 238-42
41. 41. Dushieko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995; 22: 1863-73
42. 42. Commonwealth Department of Health and Aged Care. Schedule of pharmaceutical benefits. Silverwater: McMillan Printing Group, 1999
43. 43. Commonwealth Department of Health and Aged Care. Medicare benefits schedule book. Canberra: Australian Government Publishing Service, 1999
44. 44. Department of Human Services, Victoria. Victorian Acute Health Cost Weight Study, 1996-7, prepared by Health Solutions International. Melbourne: Department of Human Services, 1997
45. 45. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-34
46. 46. Carreflo V, Bartolome J, Calstillo I. Long-term effect of interferon therapy in chronic hepatitis B. J Hepatol 1994; 20: 431-5
47. 47. Schiff E, Cianciuru Y, Kowdley K, et al. Durability of HBeAg seroconversion alter lamivudine monotherapy in controlled phase II and III trials [abstract]. Hepatology 1998; 28: 163A
48. 48. Liaw YF, Tai DJ, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 5: 493-6
49. 49. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8
50. 50. Australian Bureau of Statistics. Life tables. Canberra: Australian Bureau of Statistics, 1997. (Data on disk)
51. 51. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. Lancet 1981; II: 1129-33
52. 52. Lo K-J, Toy MJ, Chien M-C, et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis 1982; 146: 205-10
53. 53. Liaw Y-F, Lin D-Y, Chen T-J, et al. Natural course after the development of cirrhosis in chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-41
54. 54. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaskan native carriers. Arch Intern Med 1990; 150: 1051-4
55. 55. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B: the EUROHEP Study Group in hepatitis B virus and cirrhosis. Hepatology 1995; 21: 77-82
56. 56. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression to cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9
57. 57. Columbo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1991; 325: 675-80
58. 58. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994; 21: 656-66
59. 59. Department of Human Services South Australian Cancer Registry Data. Epidemiology of cancer in South Australia 1977-96. Data on file
60. 60. Hawthorne G, Richardson J, Osborne R, et al. The Assessment of Quality of Life (AQOL) instrument: construction, initial validation and utility scaling. Working paper 76. Melbourne: Centre for Health Program Evaluation, 1997
61. 61. Hawthorne G, Richardson J, Osborne R, et al. The Assessment of Quality of Life (AQOL) instrument: a psychometric measurement of health related quality of life. Qual Life Res 1999; 8: 209-24
62. 62. Bennett WG, Inoie Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65
63. 63. Data on file, Commonwealth Department of Health and Aged Services, National Hospital Cost Data Collection Public Sector 1996/7, 1998
64. 64. Johannesson M. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomised drug trials. Med Decis Making 1994; 14: 236-44
65. 65. Robinson R. Cost-utility analysis. BMJ 1993; 307: 859-62
66. 66. Sarin SK. Hepatitis B mutants: prevalence, significance and therapy [editorial]. Hepatit World 1998; 3: 1
67. 67. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-96
68. 68. Chayama K, Suzuki Y, Kobaysashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-6
69. 69. Honkoop P, de Man RA, Niesters H, et al. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998; 29: 510-4
70. 70. Perillo RP, Schalm SW, Schiff ER, et al. Predictors of HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine [abstract]. Hepatology 1999; 30 (4 Pt 2): 317A